Finally, we asked whether the AML-derived CD8+ T cells were phenotypically terminally exhausted (TEx; PD1+, TIM3+, TCF1-) or TPEx (PD1+, TCF1+, TIM3-), the latter having been shown to retain anti-tumor activity, predict clinical outcome, and expand with ICB [9, 11, 41–44]. The gene discussed is CD8A; the disease is acute myeloid leukemia.